Mechanism of factor VIIa-dependent coagulation in hemophilia blood

被引:166
作者
Butenas, S [1 ]
Brummel, KE [1 ]
Branda, RF [1 ]
Paradis, SG [1 ]
Mann, KG [1 ]
机构
[1] Univ Vermont, Dept Biochem, Burlington, VT 05405 USA
关键词
D O I
10.1182/blood.V99.3.923
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The ability of factor VIIa to initiate thrombin generation and clot formation in blood from healthy donors, blood from patients with hemophilia A, and in anti-factor IX antibody-induced ("acquired") hemophilia B blood was investigated. In normal blood, both factor VIIa-tissue factor (TF) complex and factor VIIa alone initiated thrombin generation. The efficiency of factor VIIa was about 0.0001 that of the factor VIIa-TF complex. In congenital hemophilia A blood and "acquired" hemophilia B blood in vitro, addition of 10 to 50 nM factor VIIa (pharmacologic concentrations) corrected the clotting time at all TF concentrations tested (0-100 pM) but had little effect on thrombin generation. Fibrinopeptide release and insoluble clot formation were only marginally influenced by addition of factor VIIa. TF alone had a more pronounced effect on thrombin generation; an increase in TF from 0 to 100 pM increased the maximum thrombin level in "acquired" hemophilia B blood from 120 to 480 nM. Platelet activation was considerably enhanced by addition of factor VIIa to both hemophilia A blood and "acquired" hemophilia B blood. Thus, pharmacologic, concentrations of factor VIIa cannot restore normal thrombin generation in hemophilia A and hemophilia B blood in vitro. The efficacy of factor VIIa (10-50 nM) in hemophilia blood is dependent on TF. (C) 2002 by The American Society of Hematology.
引用
收藏
页码:923 / 930
页数:8
相关论文
共 65 条
  • [51] FACTOR-VII DEFICIENCY
    RAGNI, MV
    LEWIS, JH
    SPERO, JA
    HASIBA, U
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 1981, 10 (01) : 79 - 88
  • [52] Blood clotting in minimally altered whole blood
    Rand, MD
    Lock, JB
    vantVeer, C
    Gaffney, DP
    Mann, KG
    [J]. BLOOD, 1996, 88 (09) : 3432 - 3445
  • [53] Treatment with recombinant activated factor VII in a patient with hemophilia A and an inhibitor: advantages of administration by continuous infusion over bolus intermittent injections
    Scaraggi, FA
    De Mitrio, V
    Marino, R
    Speciale, V
    Di Bari, L
    Petronelli, M
    Schiraldi, O
    [J]. BLOOD COAGULATION & FIBRINOLYSIS, 1999, 10 (01) : 33 - 38
  • [54] Continuous infusion of recombinant factor VIIa in hemophilic patients with inhibitors: Safety, monitoring, and cost effectiveness
    Schulman, S
    [J]. SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2000, 26 (04) : 421 - 424
  • [55] SCHULMAN S, 1984, ACTA MED SCAND, V215, P249
  • [56] HUMAN RECOMBINANT DNA-DERIVED ANTIHEMOPHILIC-FACTOR (FACTOR-VIII) IN THE TREATMENT OF HEMOPHILIA-A
    SCHWARTZ, RS
    ABILDGAARD, CF
    ALEDORT, LM
    ARKIN, S
    BLOOM, AL
    BRACKMANN, HH
    BRETTLER, DB
    FUKUI, H
    HILGARTNER, MW
    INWOOD, MJ
    KASPER, CK
    KERNOFF, PBA
    LEVINE, PH
    LUSHER, JM
    MANNUCCI, PM
    SCHARRER, I
    MACKENZIE, MA
    PANCHAM, N
    KUO, HS
    ALLRED, RU
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (26) : 1800 - 1805
  • [57] Recombinant factor VIIa in the treatment of bleeding in hemophilic children with inhibitors
    Shapiro, AD
    [J]. SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2000, 26 (04) : 413 - 419
  • [58] Shapiro AD, 1998, THROMB HAEMOSTASIS, V80, P773
  • [59] Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors
    Snyder, RO
    Miao, CH
    Patijn, GA
    Spratt, SK
    Danos, O
    Nagy, D
    Gown, AM
    Winther, B
    Meuse, L
    Cohen, LK
    Thompson, AR
    Kay, MA
    [J]. NATURE GENETICS, 1997, 16 (03) : 270 - 276
  • [60] FACTOR-IX CONCENTRATES FOR CLINICAL USE
    THOMPSON, AR
    [J]. SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1993, 19 (01) : 25 - 36